Compare AstraZeneca plc (AZN) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs F5 Inc — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while F5 Inc trades at $415.62 (market cap $23.44B). The key difference: AstraZeneca plc is far larger — about 10.6× F5 Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while F5 Inc pays none. Which is the better fit depends on your goals.
| AZN | FFIV | |
|---|---|---|
Market Cap | $248.14B | $23.44B |
Sector | Health | Technology |
52-Week High | $209.48 | $431.26 |
52-Week Low | $147.06 | $223.99 |
Enterprise Value | $275.41B | $22.08B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
F5 (FFIV) stock trades at $422.95, up 3.16% on the day, near its 52-week high. The company reported strong Q3 2026 earnings, beating estimates with EPS of $4.73 versus $4.00 expected, driven by 19% product revenue growth. Technical indicators show a bullish trend with support at $411 and resistance at $425. Fundamentals remain solid with revenue growth to $3.09B in 2025 and net income margin of 21.95%.
Outlook is positive given raised revenue guidance and robust cybersecurity demand, but valuation multiples like P/E of 32.98 suggest premium pricing. Risks include competitive pressures and execution challenges in sustaining high growth. Analyst consensus is Moderate Buy with a $430.43 price target, indicating modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
